72
Participants
Start Date
November 22, 2024
Primary Completion Date
March 31, 2027
Study Completion Date
September 30, 2041
Vosoritide Injection
Modified recombinant human C-type natriuretic peptide Vosoritide
Human Growth Hormone
Commercial product containing somatotropin.
RECRUITING
Icahn School of Medicine at Mount Sinai, New York
RECRUITING
Children's Hospital at Montefiore, The Bronx
RECRUITING
Hôpital de la Timone, Marseille
NOT_YET_RECRUITING
IRCCS Istituto Giannina Gaslini, Genova
RECRUITING
Nemours Children's Hospital, Delaware (Alfred I. Dupont Hospital for Children), Wilmington
RECRUITING
Children's National Medical Center, Washington D.C.
RECRUITING
Atrium Health Carolinas Medical Center, Charlotte
NOT_YET_RECRUITING
Central University Hospital of Asturias, Oviedo
NOT_YET_RECRUITING
Nicklaus Children's Hospital, Miami
RECRUITING
Kentucky Children's Hospital, Lexington
RECRUITING
M Health Fairview Pediatric Specialty Clinic - Explorer, Minneapolis
RECRUITING
Hôpital Robert-Debré, Paris
RECRUITING
Children's Medical Center Dallas, Dallas
RECRUITING
University of Texas Health Science Center at Houston (UT Health), Houston
RECRUITING
Children's Hospital Colorado, Aurora
RECRUITING
St. Luke's Children's Endocrinology and Diabetes, Boise
RECRUITING
South Paris University Hospitals - Bicetre Hospital, Le Kremlin-Bicêtre
RECRUITING
New York Medical College, Boston
RECRUITING
Angers University Hospital Center, Angers
RECRUITING
CHU de Toulouse - Hôpital des Enfants, Toulouse
Lead Sponsor
BioMarin Pharmaceutical
INDUSTRY